pubmed-article:16224068 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:16224068 | lifeskim:mentions | umls-concept:C0024432 | lld:lifeskim |
pubmed-article:16224068 | lifeskim:mentions | umls-concept:C0003009 | lld:lifeskim |
pubmed-article:16224068 | lifeskim:mentions | umls-concept:C0017337 | lld:lifeskim |
pubmed-article:16224068 | lifeskim:mentions | umls-concept:C1148932 | lld:lifeskim |
pubmed-article:16224068 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
pubmed-article:16224068 | lifeskim:mentions | umls-concept:C0920533 | lld:lifeskim |
pubmed-article:16224068 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
pubmed-article:16224068 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
pubmed-article:16224068 | pubmed:issue | 9 | lld:pubmed |
pubmed-article:16224068 | pubmed:dateCreated | 2005-10-28 | lld:pubmed |
pubmed-article:16224068 | pubmed:abstractText | Angiotensin II (Ang II) is a powerful accelerator of atherosclerosis. Herein, we describe a novel transcription mechanism through which Ang II inhibits macrophage expression of the ATP-binding cassette transporter A1 (ABCA1), a key regulator of reverse cholesterol transport. We demonstrate that chronic Ang II infusion substantially promotes macrophage infiltration, foam cell formation, and atherosclerosis in low-density lipoprotein receptor-deficient mice and significantly reduces ABCA1 expression in peripheral macrophages. Administration of the Ang II type 1 receptor blocker valsartan inhibited Ang II-induced ABCA1 mRNA repression, macrophage cholesterol accumulation, and atherosclerosis. Ang II treatment reduced ABCA1 promoter activity of in vitro cultured mouse peritoneal macrophages, inducing fos-related antigen 2 (Fra2) protein binding to an ABCA1 promoter E-box motif, a site known to negatively regulate macrophage ABCA1 transcription. Valsartan pretreatment blocked Fra2 binding to the ABCA1 promoter, and Fra2 small interfering RNA pretreatment attenuated Ang II-mediated ABCA1 transcriptional inhibition, confirming the role of Fra2 in this process. This new evidence suggests that Ang II, a well-known proinflammatory and pro-oxidative factor, alters macrophage cholesterol homeostasis by repressing ABCA1 to promote foam cell formation and atherosclerosis. | lld:pubmed |
pubmed-article:16224068 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16224068 | pubmed:language | eng | lld:pubmed |
pubmed-article:16224068 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16224068 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:16224068 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16224068 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16224068 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16224068 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16224068 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16224068 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16224068 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16224068 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16224068 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16224068 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16224068 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16224068 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16224068 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:16224068 | pubmed:month | Oct | lld:pubmed |
pubmed-article:16224068 | pubmed:issn | 1524-4571 | lld:pubmed |
pubmed-article:16224068 | pubmed:author | pubmed-author:VighB JBJ | lld:pubmed |
pubmed-article:16224068 | pubmed:author | pubmed-author:DowW HWH | lld:pubmed |
pubmed-article:16224068 | pubmed:author | pubmed-author:HigakiJitsuoJ | lld:pubmed |
pubmed-article:16224068 | pubmed:author | pubmed-author:TakataYasunor... | lld:pubmed |
pubmed-article:16224068 | pubmed:author | pubmed-author:HsuehWilla... | lld:pubmed |
pubmed-article:16224068 | pubmed:author | pubmed-author:LawRonald ERE | lld:pubmed |
pubmed-article:16224068 | pubmed:author | pubmed-author:FishbeinMicha... | lld:pubmed |
pubmed-article:16224068 | pubmed:author | pubmed-author:BlaschkeFlori... | lld:pubmed |
pubmed-article:16224068 | pubmed:author | pubmed-author:CollinsAlan... | lld:pubmed |
pubmed-article:16224068 | pubmed:author | pubmed-author:TangiralaRaje... | lld:pubmed |
pubmed-article:16224068 | pubmed:author | pubmed-author:BruemmerDenni... | lld:pubmed |
pubmed-article:16224068 | pubmed:author | pubmed-author:LyonChristoph... | lld:pubmed |
pubmed-article:16224068 | pubmed:author | pubmed-author:DaleyWilliamW | lld:pubmed |
pubmed-article:16224068 | pubmed:author | pubmed-author:CaglayanEvren... | lld:pubmed |
pubmed-article:16224068 | pubmed:issnType | Electronic | lld:pubmed |
pubmed-article:16224068 | pubmed:day | 28 | lld:pubmed |
pubmed-article:16224068 | pubmed:volume | 97 | lld:pubmed |
pubmed-article:16224068 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:16224068 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:16224068 | pubmed:pagination | e88-96 | lld:pubmed |
pubmed-article:16224068 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
pubmed-article:16224068 | pubmed:meshHeading | pubmed-meshheading:16224068... | lld:pubmed |
pubmed-article:16224068 | pubmed:meshHeading | pubmed-meshheading:16224068... | lld:pubmed |
pubmed-article:16224068 | pubmed:meshHeading | pubmed-meshheading:16224068... | lld:pubmed |
pubmed-article:16224068 | pubmed:meshHeading | pubmed-meshheading:16224068... | lld:pubmed |
pubmed-article:16224068 | pubmed:meshHeading | pubmed-meshheading:16224068... | lld:pubmed |
pubmed-article:16224068 | pubmed:meshHeading | pubmed-meshheading:16224068... | lld:pubmed |
pubmed-article:16224068 | pubmed:meshHeading | pubmed-meshheading:16224068... | lld:pubmed |
pubmed-article:16224068 | pubmed:meshHeading | pubmed-meshheading:16224068... | lld:pubmed |
pubmed-article:16224068 | pubmed:meshHeading | pubmed-meshheading:16224068... | lld:pubmed |
pubmed-article:16224068 | pubmed:meshHeading | pubmed-meshheading:16224068... | lld:pubmed |
pubmed-article:16224068 | pubmed:meshHeading | pubmed-meshheading:16224068... | lld:pubmed |
pubmed-article:16224068 | pubmed:meshHeading | pubmed-meshheading:16224068... | lld:pubmed |
pubmed-article:16224068 | pubmed:meshHeading | pubmed-meshheading:16224068... | lld:pubmed |
pubmed-article:16224068 | pubmed:meshHeading | pubmed-meshheading:16224068... | lld:pubmed |
pubmed-article:16224068 | pubmed:meshHeading | pubmed-meshheading:16224068... | lld:pubmed |
pubmed-article:16224068 | pubmed:meshHeading | pubmed-meshheading:16224068... | lld:pubmed |
pubmed-article:16224068 | pubmed:year | 2005 | lld:pubmed |
pubmed-article:16224068 | pubmed:articleTitle | Transcriptional repression of ATP-binding cassette transporter A1 gene in macrophages: a novel atherosclerotic effect of angiotensin II. | lld:pubmed |
pubmed-article:16224068 | pubmed:affiliation | Division of Endocrinology, Diabetes, and Hypertension, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA. | lld:pubmed |
pubmed-article:16224068 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:16224068 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
pubmed-article:16224068 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
pubmed-article:16224068 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16224068 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16224068 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16224068 | lld:pubmed |